Prednisone for Heart Failure Patients With Hyperuricemia

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

Also called NCT02129764

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 205 participants (enrolled count) (from the registry)
Sponsor
Hebei Medical University (from the registry)
Registry
  • NCT NCT02129764
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02129764. Randomized; no masking; primary purpose treatment. Start 2013-12 (actual); primary completion 2018-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prednisone for Heart Failure Patients With Hyperuricemia
Acronym
PUSH-PATH-2
Condition
Heart Failure, Hyperuricemia
Intervention (Drug)
Prednisone
Intervention (Drug)
Allopurinol
Lead sponsor
Hebei Medical University (class: other)

Record details

Record id
cardio:ct-nct02129764
Content hash
c8efbedaca763aacc564ec7c88e8f8de079114f071b93d719645c1213b407f0e